B. Riley Securities Reiterates Buy on Anika Therapeutics, Lowers Price Target to $17
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Madison El-Saadi reiterates Anika Therapeutics (NASDAQ:ANIK) with a Buy and lowers the price target from $23 to $17.
B. Riley Securities analyst Madison El-Saadi reiterates Anika Therapeutics (NASDAQ:ANIK) with a Buy and lowers the price target from $23 to $17.
